S.Korea to mix-and-match COVID-19 vaccine doses for 760,000 people | Inquirer News

S.Korea to mix-and-match COVID-19 vaccine doses for 760,000 people

/ 03:15 PM June 18, 2021

FILE PHOTO: A health worker gets a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at a COVID-19 vaccination center in Seoul, South Korea, March 10, 2021. REUTERS/Kim Hong-Ji

 

SEOUL  — Some 760,000 South Koreans who have received the first dose of AstraZeneca Plc’s COVID-19 vaccine will be offered Pfizer Inc’s vaccine as a second shot due to shipment delays by global vaccine sharing scheme COVAX, the government said.

ADVERTISEMENT

Several countries, including Canada and Spain, have already approved such dose-mixing mainly due to concerns about rare and potentially fatal blood clots linked to the AstraZeneca vaccine.

FEATURED STORIES

A Spanish study found that giving a dose of the Pfizer shot to people who already received the AstraZeneca vaccine is highly safe and effective, according to preliminary results.

Some 835,000 doses of AstraZeneca’s vaccine from COVAX were scheduled to arrive by the end of June, which South Korea planned to use mainly as a second shot for around 760,000 health and frontline workers who had received their first dose in April.

The shipment is delayed to July or later, while the country had used up available AstraZeneca reserves to meet stronger than expected participation in its vaccination campaign which helped the country meet its first-half inoculation target ahead of schedule.

Over 27% of its 52 million population have been inoculated with at least one dose of a coronavirus vaccine as of Thursday, and the country is on track to meet a target of 70% by September and reach herd immunity before November.

The government expects to receive 80 million doses of COVID-19 vaccines in the third quarter including 10 million in July. They are from AstraZeneca, Pfizer, Johnson & Johnson, and Moderna.

South Korea said last month it will conduct a clinical trial that mixes COVID-19 doses from AstraZeneca with those from Pfizer and others.

ADVERTISEMENT

It has so far run a trial in 100 health workers to examine the formation of antibodies and other immune effects, Korea Disease Control and Prevention Agency (KDCA) director Jeong Eun-kyeong told a briefing on Thursday.

South Korea reported 507 new infections by midnight on Thursday, for a tally of 150,238 cases, the KDCA said, with a death toll of 1,996 since the pandemic began.

/MUF
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: COVID-19, South korea, Vaccines

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.